Lan Beppu
Overview
Explore the profile of Lan Beppu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qu X, Stevens E, Fitzgibbon M, Beppu L, Monahan T, Yeung C, et al.
Transplant Cell Ther
. 2024 Dec;
31(3):170.e1-170.e8.
PMID: 39722322
Background: Despite its known superior diagnostic yield for chromosomal anomalies compared with karyotype and fluorescence in situ hybridization (FISH) studies, chromosome genomic array testing (CGAT) is not used as a...
2.
Ueda Oshima M, Higgins J, Jenkins I, Randolph T, Smith T, Valentine 3rd C, et al.
Sci Transl Med
. 2024 Oct;
16(770):eado5108.
PMID: 39441907
After allogeneic hematopoietic cell transplantation (HCT), a very small number of donor stem cells reconstitute the recipient hematopoietic system, whereas the donor is left with a near-normal pool of stem...
3.
Sala-Torra O, Beppu L, Wu Q, Welch E, Berthier E, Radich J, et al.
Leukemia
. 2024 Jun;
38(8):1822-1824.
PMID: 38879611
No abstract available.
4.
Yeung C, Eacker S, Sala-Torra O, Beppu L, Woolston D, Liachko I, et al.
medRxiv
. 2024 Jun;
PMID: 38853970
Background: Cytogenetic analysis encompasses a suite of standard-of-care diagnostic testing methods that is routinely applied in cases of acute myeloid leukemia (AML) to assess chromosomal changes that are clinically relevant...
5.
Sala-Torra O, Reddy S, Hung L, Beppu L, Wu D, Radich J, et al.
PLOS Glob Public Health
. 2023 Sep;
3(9):e0002267.
PMID: 37699001
Recurrent gene fusions are common drivers of disease pathophysiology in leukemias. Identifying these structural variants helps stratify disease by risk and assists with therapy choice. Precise molecular diagnosis in low-and-middle-income...
6.
Dillon L, Higgins J, Nasif H, Othus M, Beppu L, Smith T, et al.
Haematologica
. 2023 Aug;
109(2):401-410.
PMID: 37534515
The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be...
7.
Dillon L, Higgins J, Nasif H, Othus M, Beppu L, Smith T, et al.
medRxiv
. 2023 Apr;
PMID: 37034683
The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be...
8.
Shelton D, Bhagavatula P, Sepulveda N, Beppu L, Gandhi S, Qin D, et al.
PLoS One
. 2022 Mar;
17(3):e0265278.
PMID: 35298544
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22...
9.
Scott S, Cartwright A, Francis S, Whitby L, Sanzone A, Mulder A, et al.
Br J Haematol
. 2021 Jun;
194(1):53-60.
PMID: 34114218
Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kinase (BCR-ABL1) mRNA levels by reverse transcription quantitative polymerase chain reaction (RTqPCR) has been critical to treatment...
10.
Schmitt M, Pritchard J, Leighow S, Aminov B, Beppu L, Kim D, et al.
Clin Cancer Res
. 2018 Jul;
24(21):5321-5334.
PMID: 30042204
Sequential treatment with targeted therapies can result in complex combinations of resistance mutations in drug targets. This mutational complexity has spurred the development of pan-target inhibitors, i.e., therapies for which...